FrancophonIA/ELRC3.0 huggingface dataset:
English: It is not intended to provide practical advice on how to use Innovax-ILT.
Estonian: Hindamisaruandes ei anta vaktsiini Innovax-ILT kasutamise praktilisi nõuandeid.
English: Since Innovax-ILT is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Estonian: Kuna Innovax-ILT on elusvaktsiin, eritub vaktsiini tüvi vaktsineeritud lindudelt ja võib levida kalkunitele.
English: Innovax-ILT contains live turkey herpesvirus strain HVT/ILT-138.
Estonian: Innovax-ILT sisaldab elus kalkuni herpesviiruse tüve HVT/ILT-138.
English: ILT is an infection of the airways which may affect growth and decrease egg production in chickens.
Estonian: ILT on hingamisteede infektsioon, mis võib mõjutada kanade kasvu ja vähendada munade tootmist.
English: Avian infectious laryngotracheitis and Marek's disease vaccine (live recombinant)
Estonian: lindude infektsioosse larüngotrahheiidi ja Mareki tõve vaktsiin (elus, rekombinantne)
English: Innovax-ILT is a vaccine containing turkey herpesvirus serotype 3, a type of herpesvirus which is closely related to MD virus but does not cause disease in chickens.
Estonian: Innovax-ILT on vaktsiin, mis sisaldab kalkuni herpesviiruse serotüüpi 3, mis on MD viirusega lähedalt seotud herpesviiruse tüüp, kuid ei tekita kanadel haigust.
English: MD is another herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs.
Estonian: MD on samuti kanade herpesviiruse infektsioon, mis võib põhjustada tiibade ja jalgade halvatust ning põhjustab kasvajate teket eri organites.
English: Protection against MD starts 9 days after vaccination and lasts for life.
Estonian: Kaitse MD vastu tekib 9 päeva pärast vaktsineerimist ja püsib kogu elu.
English: Innovax-ILT is a veterinary vaccine used to protect chickens against infectious laryngotracheitis (ILT) and Marek's disease (MD).
Estonian: Innovax-ILT on veterinaarvaktsiin, mida kasutatakse kanade kaitsmiseks infektsioosse larüngotrahheiidi (ILT) ja Mareki tõve (MD) eest.
English: The level of protection in general was higher when Innovax-ILT was given alone.
Estonian: Üldiselt oli kaitse tase kõrgem, kui manustati ainult vaktsiini Innovax-ILT.
English: The vaccine can be given to one-day-old chicks as a single injection under the skin in the neck.
Estonian: Vaktsiini tohib anda ühe päeva vanustele tibudele ühe subkutaanse süstena kaela.
English: A field trial in chickens was performed to evaluate the effects of the vaccine against ILT and MD. Mortality was low, no disease related signs were observed and the condition of the chickens was good throughout the trial, indicating effectiveness of the vaccine.
Estonian: Suremus oli väike, ei täheldatud ühtki haigusega seotud tunnust ja kanade seisund oli kogu uuringu kestel hea, mis viitab vaktsiini efektiivsusele.
English: In the future if the animals are exposed to a similar virus the immune system will be able to respond more quickly.
Estonian: Kui linnud puutuvad sarnase viirusega hiljem kokku, tekivad antikehad kiiremini.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Innovax-ILT, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Innovax-ILT ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body.
Estonian: Kanad nakatuvad noorelt, hingates sisse viirust sisaldavat kõõma (helbed nahal), mis võib olla nakkav veel mitu kuud pärast kehalt langemist.
English: What are the risks associated with Innovax-ILT?
Estonian: Mis riskid vaktsiiniga Innovax-ILT kaasnevad?
English: To evaluate the effects of the vaccine against MD, chickens vaccinated either with Innovax-ILT alone or Innovax-ILT mixed with Nobilis Rismavac (a vaccine which also protects against Marek's disease) were infected with very virulent strains of the MD virus.
Estonian: Selleks, et hinnata vaktsiini toimet MD vastu, nakatati kas ainult vaktsiiniga Innovax-ILT või vaktsiinide Innovax-ILT ja Nobilis Rismavac (vaktsiin, mis kaitseb ka Mareki tõve eest) seguga ravitud kanu MD viiruse väga virulentsete tüvedega.
English: When Innovax-ILT was applied mixed with Nobilis Rismavac, the start of protection against ILT was delayed by up to 10 weeks after vaccination.
Estonian: Vaktsiinide Innovax-ILT ja Nobilis Rismavac segu manustamisel viibis ILT vastase kaitse teke kuni 10 nädalat pärast vaktsineerimist.
English: When Innovax-ILT is given to chickens, the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it.
Estonian: Kui kanadele manustatakse vaktsiini Innovax-ILT, peab lindude immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: In a second challenge study the effectiveness of the vaccination with Innovax-ILT alone and InnovaxILT mixed with Nobilis Rismavac was also examined by evaluation of protection after infection under laboratory conditions with the ILT virus.
Estonian: Teises katselise nakatamise uuringus uuriti ainult vaktsiiniga Innovax-ILT ja vaktsiinide Innovax-ILT ja Nobilis Rismavac seguga vaktsineerimise efektiivsust, hinnates, millal tekib kaitse pärast katselist nakatamist ILT viirusega laboritingimustes.
English: Chickens were taken from the field trial and challenged (exposed to infection) in the laboratory to demonstrate protection after vaccination.
Estonian: Väliuuringus osalenud kanu nakatati katseliselt laboratooriumis, tõendamaks, et vaktsineerimise järel tekib kaitse.
English: For practical information about using Innovax-ILT, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Innovax-ILT kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: How does Innovax-ILT work?
Estonian: Kuidas Innovax-ILT toimib?
English: When Innovax-ILT is given mixed with Nobilis Rismavac protection against MD starts at 5 days after vaccination.
Estonian: Vaktsiinide Innovax-ILT ja Nobilis Rismavac segu manustamisel tekib kaitse MD vastu 5. päeval pärast vaktsineerimist.
English: What benefits of Innovax-ILT have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Innovax-ILT kasulikkus?
English: Innovax-ILT is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription.
Estonian: Vaktsiini Innovax-ILT turustatakse suspensiooni ja lahustina, millest valmistatakse süstesuspensioon.
English: Chickens showed significant protection after both vaccination with Innovax-ILT alone and Innovax-ILT mixed with Nobilis Rismavac.
Estonian: Kanadel tekkis märkimisväärne kaitse pärast vaktsineerimist nii ainult vaktsiiniga Innovax-ILT kui ka vaktsiinide Innovax-ILT ja Nobilis Rismavac seguga.
English: Chickens showed varying levels of protection after vaccination with either Innovax-ILT alone or Innovax-ILT mixed with Nobilis Rismavac.
Estonian: Kanadel tekkis eri tasemel kaitse pärast vaktsineerimist nii ainult vaktsiiniga Innovax-ILT kui ka vaktsiinide Innovax-ILT ja Nobilis Rismavac seguga.
English: How is Innovax-ILT used?
Estonian: Kuidas vaktsiini Innovax-ILT kasutatakse?
English: It is available as tablets (50, 100, 200, 300 and 400 mg).
Estonian: Seda turustatakse tablettidena (50, 100, 200, 300 ja 400 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Trobalt on 28 March 2011.
Estonian: Euroopa Komisjon andis Trobalti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. märtsil
English: Other information about Trobalt
Estonian: Muu teave Trobalti kohta
English: The full EPAR for Trobalt can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Trobalti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Trobalt retigabine
Estonian: Trobalt retigabiin
English: What measures are being taken to ensure the safe use of Trobalt?
Estonian: Mis meetmeid võetakse, et tagada Trobalti kasutamise ohutus?
English: The CHMP decided that the benefits of Trobalt are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Trobalti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The effect of Trobalt at 600 mg a day was inconclusive in this study.
Estonian: Trobalti 600 mg ööpäevase annuse efektiivsust ei olnud võimalik uuringu põhjal järeldada.
English: Treatment with Trobalt starts with one 100 mg tablet three times a day for one week; the dose is then increased weekly by 50 mg per dose according to the patient's response.
Estonian: Ravi Trobaltiga alustatakse ühe 100 mg annusega 3 korda ööpäevas 1 nädala jooksul, seejärel suurendatakse annust iga nädal 50 mg võrra annuse kohta lähtuvalt patsiendi ravivastusest.
English: In the other two studies, the main measure of effectiveness was the number of patients whose number of seizures was at least halved.
Estonian: Kahes ülejäänud uuringus oli efektiivsuse põhinäitaja nende patsientide arv, kelle epilepsiaepisoodid harvenesid vähemalt kaks korda.
English: However, because of the risk of retinal discolouration, which could possibly result in impaired vision, the CHMP concluded that the use of Trobalt should be restricted only to those patients for whom other anti-epileptic medicines have proved inadequate or have not been tolerated.
Estonian: Ent silma võrkkesta pigmendimuutuse tõttu, mis võib põhjustada nägemiskahjustust, otsustas inimravimite komitee piirata Trobalti kasutamist üksnes nendele patsientidele, kellel teised epilepsiaravimid on osutunud ebapiisavaks või kes neid ei talu.
English: Epilepsy is caused by excessive electrical activity in the nerve cells of the brain.
Estonian: Epilepsiat põhjustab aju närvirakkude liigne elektriline talitlus.
English: Lower doses should be used in older patients and in patients with moderate or severe liver or kidney problems.
Estonian: Väiksemat annust kasutatakse vanematel patsientidel ja mõõdukate või raskete maksa- või neeruhäiretega patsientidel.
English: Trobalt has been compared with placebo (a dummy treatment) in three main studies involving a total of 1,244 patients whose seizures were not adequately controlled with other anti-epileptic medicines.
Estonian: Trobaltit võrreldi platseeboga (näiv ravim) kolmes põhiuuringus, milles osales kokku 1244 patsienti, kelle epilepsiaepisoodid ei allunud piisavalt ravile muude epilepsiaravimitega.
English: This is a summary of the European public assessment report (EPAR) for Trobalt.
Estonian: See on ravimi Trobalt Euroopa avaliku hindamisaruande kokkuvõte.
English: What is Trobalt?
Estonian: Mis on Trobalt?
English: What is the risk associated with Trobalt?
Estonian: Mis riskid Trobaltiga kaasnevad?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Trobalt.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The company that makes Trobalt must ensure that doctors who are expected to prescribe Trobalt receive an information pack containing important safety information, including information on the risk of pigment changes in the eye and discolouration of the nails, lips and skin, and on the need for a full eye examination at the start of treatment and at least every 6 months during treatment.
Estonian: Trobalti tootja peab tagama, et kõik Trobaltit määrata võivad arstid saavad teabepakme tähtsa ohutusteabega, sh teabega silma võrkkesta pigmendimuutuse ja küünte, huulte ja naha värvimuutuse riski kohta, ning et ravi alguses ja vähemalt kaks korda aastas tehtaks täielik silmauuring.
English: The CHMP noted that Trobalt is effective at reducing the number of seizures.
Estonian: Inimravimite komitee märkis, et Trobalt on epilepsiaepisoodide arvu vähendamisel efektiivne.
English: For the full list of all side effects reported with Trobalt, see the package leaflet.
Estonian: Trobalti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It will also include information on some less common side effects that have been reported with the medicine, such as problems with passing urine, prolonged QT interval (an alteration of the electrical activity of the heart) and hallucinations (seeing or hearing things that are not there).
Estonian: Teabepakmes peab olema ka teave muude vähemtähtsate tavaliste kõrvalnähtude kohta, millest on ravimi kasutamisel teatatud, nt urineerimisprobleemid, pikenenud QT-intervall (südame elektrilise talitluse teatud muutus) ja hallutsinatsioonid (ebareaalsete asjade nägemine või kuulmine).
English: Trobalt is a medicine that contains the active substance retigabine.
Estonian: Trobalt on ravim, mis sisaldab toimeainena retigabiini.
English: For more information about treatment with Trobalt, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Trobaltiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Trobalt at a maintenance dose of 600, 900 or 1,200 mg a day or placebo was taken for 8 weeks in the first study and 12 weeks in the other two studies.
Estonian: Patsientidele manustati Trobalti säilitusannus 600 mg, 900 mg või 1200 mg ööpäevas või platseebot esimeses uuringus 8 ja ülejäänud kahes uuringus 12 nädala jooksul.
English: For more information on how to use Trobalt, including detailed recommendations for different patients groups, see the summary of product characteristics (also part of the EPAR).
Estonian: Lisateave Trobalti kasutamise kohta ja üksikasjalikud soovitused kasutamiseks eri patsiendirühmadel on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: The most common side effects with Trobalt (seen in more than 1 patient in 10) are dizziness, somnolence (sleepiness), fatigue (tiredness) as well as pigment changes (discolouration) of parts of the eye (including the retina, the light sensitive membrane at the back of the eye) and discolouration of the nails, lips and skin, which have been reported after several years of treatment.
Estonian: Trobalti kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peapööritus, unisus, väsimus, samuti silmaosade (sh võrkkesta) pigmendimuutused (värvimuutused) ning küünte, huulte ja naha värvimuutus, mida on esinenud pärast mitmeaastast ravi.
English: Why has Trobalt been approved?
Estonian: Miks Trobalt heaks kiideti?
English: Trobalt is used in combination with other anti-epileptic medicines to treat adults with drug-resistant partial-onset seizures (epileptic fits) that cannot be treated with other combinations of medicines.
Estonian: Trobaltit kasutatakse koos teiste epilepsiaravimitega, et ravida täiskasvanuil ravimiresistentseid teistele ravimikombinatsioonidele allumatuid partsiaalseid epilepsiaepisoode.
English: In the first study, Trobalt at 900 mg a day and 1,200 mg a day was more effective than placebo and reduced the number of seizures per month by 29% and 35% respectively.
Estonian: Esimeses uuringus oli Trobalt 900 mg ja 1200 mg ööpäevane annus efektiivsem kui platseebo ja vähendas epilepsiaepisoodide sagedust kuus vastavalt 29% ja 35% võrra.
English: The recommended maintenance dose is between 600 mg a day and a maximum of 1,200 mg a day.
Estonian: Soovitatav säilitusannus on 600-1200 mg ööpäevas.
English: In the second study, seizures were at least halved in 39% (61 out of 158 patients) of the patients on 600 mg Trobalt a day and in 47% (70 out of 149 patients) of the patients on 900 mg a day, compared with 19% (31 out of 164) of the patients on placebo.
Estonian: Teises uuringus oli patsiente, kellel harvenesid vähenesid epilepsiaepisoodid vähemalt kaks korda, ööpäevas 600 mg Trobaltit manustanutest 39% (61 patsienti 158st) ja 900 mg manustanutest 47% (70 patsienti 149st) ning platseeborühmas 19% (13 patsienti 164st).
English: This is a type of epilepsy where too much electrical activity in one part of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness or a sudden sense of fear.
Estonian: Partsiaalsed epilepsiaepisoodid on epilepsia vorm, kus aju ühe poolkera elektriline liigtalitlus tekitab selliseid sümptomeid nagu ühe kehapoole järsud tõmblused, kuulmis-, haistmis- või nägemishäired, tuimus või äkiline hirmutunne.
English: Trobalt must not be used in people who are hypersensitive (allergic) to retigabine or any of the other ingredients.
Estonian: Trobaltit ei tohi kasutada patsiendid, kes on retigabiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: In the first study, the main measure of effectiveness was the change in the number of seizures per month.
Estonian: Esimeses uuringus oli efektiivsuse põhinäitaja ühes kuus esinenud epilepsiaepisoodide arvu muutus.
English: The active substance in Trobalt, retigabine, is an anti-epileptic medicine.
Estonian: Trobalti toimeaine retigabiin on epilepsiaravim.
English: What benefit has Trobalt shown during the studies?
Estonian: Milles seisneb uuringute põhjal Trobalti kasulikkus?
English: Trobalt was more effective than placebo in reducing the number of seizures.
Estonian: Trobalt oli epilepsiaepisoodide sageduse vähendamisel efektiivsem kui platseebo.
English: It is used in epilepsy with or without ‘secondary generalisation' (when the excessive electrical activity reaches the whole brain).
Estonian: Ravimit kasutatakse sekundaarse generaliseerumisega (elektriline liigtalitlus levib kogu ajule) või ilma sekundaarse generaliseerumiseta epilepsia raviks.
English: In the third study, seizures were at least halved in 56% (66 out of 119 patients) of the patients taking 1,200 mg Trobalt a day, compared with 23% (31 out of 137) of the patients on placebo.
Estonian: Kolmandas uuringus oli patsiente, kellel harvenesid epilepsiaepisoodid vähemalt kaks korda, ööpäevas 1200 mg Trobaltit manustanutest 56% (66 patsienti 199st) ja platseeborühmas 23% (31 patsienti 137st).
English: This will stop further transmission of electrical impulses thereby preventing epileptic seizures.
Estonian: Trobalti toimel on kaaliumikanalid avatud, mis lõpetab elektriimpulsside edasise leviku ja ennetab epilepsiaepisoodide tekke.
English: How has Trobalt been studied?
Estonian: Kuidas Trobaltit uuriti?
English: How is Trobalt used?
Estonian: Kuidas Trobaltit kasutatakse?
English: What is Trobalt used for?
Estonian: Milleks Trobaltit kasutatakse?
English: This compared with a reduction of 13% in the placebo group.
Estonian: Platseeborühmas vähenesid epilepsiaepisoodid 13% võrra.
English: These are pores that let potassium move in and out of the cell and play a role in terminating electrical impulses.
Estonian: Trobalt mõjutab aju närvirakkude kaaliumikanaleid, mille kaudu kaalium liigub närvirakku ja väljub sellest ning osaleb elektriimpulsside katkestamises.
English: How does Trobalt work?
Estonian: Kuidas Trobalt toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Trobalt on retseptiravim.
English: Veltassa patiromer
Estonian: Veltassa patiromeer
English: What measures are being taken to ensure the safe and effective use of Veltassa?
Estonian: Mis meetmed võetakse, et tagada Veltassa ohutu ja efektiivne kasutamine?
English: The maximum dose is 25.2 g once a day.
Estonian: Suurim annus on 25,2 g üks kord ööpäevas.
English: The full EPAR for Veltassa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Veltassa kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Veltassa and what is it used for?
Estonian: Mis on Veltassa ja milleks seda kasutatakse?
English: Hyperkalaemia can cause serious heart problems and muscle weakness.
Estonian: Hüperkaleemia võib põhjustada tõsiseid südameprobleeme ja lihasnõrkust.
English: The Veltassa mixture should be taken with food and at least 3 hours before or after any other medicines the patient takes by mouth.
Estonian: Veltassa segu tuleb võtta koos söögiga vähemalt 3 tundi enne või pärast mis tahes muu suukaudse ravimi kasutamist.
English: The European Medicines Agency decided that Veltassa's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Veltassa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Veltassa is available as sachets (8.4, 16.8 and 25.2 g) of patiromer containing a powder for mixing with water or some fruit juices and taking by mouth.
Estonian: Veltassat turustatakse kotikestes (8,4, 16,8 ja 25,2 g), mis sisaldavad patiromeeri pulbrina veega või teatavate puuviljamahladega segamiseks ja suukaudseks manustamiseks.
English: What are the risks associated with Veltassa?
Estonian: Mis riskid Veltassaga kaasnevad?
English: Why is Veltassa approved?
Estonian: Miks Veltassa heaks kiideti?
English: How is Veltassa used?
Estonian: Kuidas Veltassat kasutatakse?
English: The recommended starting dose is 8.4 g once a day.
Estonian: Soovitatav algannus on 8,4 g üks kord ööpäevas.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Veltassa have been included in the summary of product characteristics and the package leaflet.
Estonian: Veltassa ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The doctor then adjusts the dose at intervals of at least one week, based on the patient's blood levels of potassium.
Estonian: Seejärel kohandab arst annust vähemalt iga nädala järel vastavalt patsiendi vere kaaliumisisaldusele.
English: The side effects are relatively moderate but the doctor should take them into account when considering treatment with Veltassa.
Estonian: Kõrvalnähud on võrdlemisi mõõdukad, kuid Veltassa-ravi kaalumisel peab arst neid arvesse võtma.
English: It is not intended to provide practical advice on how to use Veltassa.
Estonian: Hindamisaruandes ei anta Veltassa kasutamise praktilisi nõuandeid.
English: The most common side effects with Veltassa (which may affect more than 1 in 100 people) are those affecting the digestive system (constipation, diarrhoea, abdominal pain and wind) and blood tests showing low levels of magnesium in the blood.
Estonian: Veltassa kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 100st) on seedetrakti kõrvalnähud (kõhukinnisus, kõhulahtisus, kõhuvalu ja puhitus) ja väike magneesiumisisaldus veres.
English: Other information about Veltassa
Estonian: Muu teave Veltassa kohta
English: When Veltassa is taken by mouth, the active substance, patiromer, remains in the gut where it attaches tightly to potassium to form a compound that is then passed out in the stool.
Estonian: Veltassa suukaudsel manustamisel jääb toimeaine patiromeer soolestikku ning kinnitub tugevalt kaaliumiosakestele, moodustades ühendi, mis seejärel eritub väljaheitega.
English: Veltassa contains the active substance patiromer.
Estonian: Veltassa sisaldab toimeainena patiromeeri.